Clinical Trial Detail

NCT ID NCT03417882
Title GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors BrightPath Biotherapeutics
Indications

lung non-small cell carcinoma

Therapies

GRN-1201 + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.